News
PFE-WI
35.40
0.00%
0.00
MDB Capital report says retatrutide hits 28.7% weight loss, shifts obesity drug race to IP
PUBT · 1h ago
Pfizer's blood cancer drug meets main goal in late-stage trial
Reuters · 4h ago
Pfizer says Phase 3 MagnetisMM-5 trial meets primary endpoint for ELREXFIO in myeloma
PUBT · 5h ago
PFIZER - MAGNETISMM-5 TRIAL ONGOING TO ASSESS OVERALL SURVIVAL
Reuters · 5h ago
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings
Reuters · 8h ago
PFIZER <PFE.N>: JEFFERIES RAISES TARGET PRICE TO $35 FROM $34
Reuters · 12h ago
Hikma settles Pfizer Vyndamax patent litigation, generic entry set for June 2031
PUBT · 22h ago
BUZZ-BridgeBio slips as Pfizer patent deal disappoints investors
Reuters · 1d ago
Pfizer settles Vyndamax patent suits with Dexcel, Hikma, Cipla, extends US expiry to 2031
PUBT · 1d ago
PFIZER: AS A RESULT OF SETTLEMENT, REVENUES ARE NOW EXPECTED TO REMAIN RELATIVELY STABLE FROM 2028 THROUGH MID-2031
Reuters · 1d ago
PFIZER -
Reuters · 1d ago
Pfizer shareholders approve amended 2019 stock plan at annual meeting
PUBT · 1d ago
Armata Pharmaceuticals appoints Pfizer executive Daniel Gilmer to board
PUBT · 2d ago
Fulcrum Therapeutics names Marea CEO Josh Lehrer to board as independent director
PUBT · 2d ago
Relay Therapeutics plans Phase 3 trial of zovegalisib-atirmociclib triplet in breast cancer
PUBT · 2d ago
RELAY THERAPEUTICS INC - ENTERS SUPPLY AGREEMENT WITH PFIZER FOR ATIRMOCICLIB IN PHASE 3 TRIAL
Reuters · 2d ago
BMS, Pfizer partner with Mark Cuban Cost Plus Drugs to offer Eliquis online
PUBT · 5d ago
PFIZER - ELIQUIS AVAILABLE ON COST PLUS DRUGS FROM APRIL 27, 2026 AT $345 FOR 30-DAY SUPPLY
Reuters · 5d ago
BRISTOL MYERS SQUIBB AND PFIZER TO MAKE ELIQUIS® (APIXABAN) AVAILABLE VIA MARK CUBAN COST PLUS DRUG COMPANY
Reuters · 5d ago
MEDIA-Mark Cuban’s online pharmacy to sell blockbuster blood thinner Eliquis- Bloomberg News
Reuters · 5d ago
More
Webull provides a variety of real-time PFE-WI stock news. You can receive the latest news about PFIZER through multiple platforms. This information may help you make smarter investment decisions.
About PFE-WI
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.